Blank Bio
AI-powered RNA biology
San Francisco, CA, US
Blank Bio develops computational foundation models that understand RNA sequences and properties. Their flagship model, Orthrus, excels at mRNA property prediction and design with state-of-the-art performance, offering capabilities in cfRNA analysis, biomarker discovery, and lncRNA essentiality prediction. The company provides open-source models for industry partners and seeks collaborations to refine them for specific therapeutic applications.
Source: HealthTechAlpha
HealthTechAlpha provided this information. To learn more and get deep data on all digital health companies, please visit them here.
Visit HealthTechAlpha →
How We Help
Problem Statement
Existing computational approaches struggle to accurately predict mRNA properties and design effective RNA therapeutics due to limitations in understanding the functional implications of genetic sequences, where many mutations do not affect fitness.
Core Technology
Computational foundation models that understand RNA sequences and properties; mRNA property prediction and design with state-of-the-art performance; cfRNA analysis and isoform characterization capabilities; biomarker discovery for patient stratification; target identification through lncRNA essentiality prediction; small molecule targeting guidance for RNA-based drugs; Orthrus 10-million parameter RNA foundation model; contrastive learning with joint embedding architecture.
Key Differentiators
Flagship model excels at mRNA property prediction and simulates laboratory experiments; Core capabilities include mRNA property prediction and design with state-of-the-art performance; Recognizes that 90% of genomic sequences can mutate without affecting fitness, making next-token prediction suboptimal; Uses contrastive learning with joint embedding architecture for functional understanding; Orthrus uses domain-specific learning that rejects standard NLP approaches; Contrastive learning objective creates positive pairs from splice isoforms across 10 model organisms; Uses orthologous sequences from 400+ mammalian species from Zoonomia Project
Clinical Focus
Therapeutics; Diagnostics
Company Info
- Business Model
- Hybrid
- Founded
- 2025
- Total Funding
- 500,000
- Website
- www.blank.bio
Categories
Technologies
Clinical & IP
Clinical Validation
Foundation models outperform 59 research models in mRNA property prediction. Introduced mRNABench benchmarking suite. Active partnerships with Sanofi, GSK, and Arc Institute. Pre-commercialization stage with early access program
MedStartr Index Score
?What do you think of Blank Bio?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.